Tobira to present at major liver disease conference
March 20, 2015 - 7:30 AM EDT
Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease
SOUTH SAN FRANCISCO, Calif., March 20, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it will be presenting at the "Industry Colloquium: Novel Targets and Therapies in Liver Disease" a conference organized by the American Association for the Study of Liver Disease (AASLD). The conference is being held today and tomorrow, March 21st, in Durham, NC.
"This is an exciting time in the development of novel therapies to treat patients suffering from NASH and liver fibrosis," commented Laurent Fischer, M.D., chairman and CEO of Tobira Therapeutics. "We look forward to presenting supportive new data and a program overview for cenicriviroc in NASH at such an important event for the hepatology community."
Tobira's cenicriviroc (CVC) presentations at AASLD's Industry Colloquium will include:
Friday, March 20th
Lunch and Poster Session: 12:20 PM – 1:45 PM
Oral, Dual CCR2/CCR5 Antagonist Cenicriviroc Leads To Dose-Dependent Decreases In Monocyte Recruitment In A Thioglycollate-Induced Model Of Peritonitis (Poster #8)
F. Tacke; D. Poulin; H. Jenkins; G. Wolfgang; E. Lefebvre
Saturday, March 21st
Session VII: NASH: Clinical Endpoints and Drug Development (II): 9:20 AM – 9:40 AM
Cenicriviroc as Treatment for NASH in Patients with Liver Fibrosis
Eric A. Lefebvre, MD – Chief Medical Officer, Tobira Therapeutics
About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV-1. The company's lead product, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV-1. Tobira is actively enrolling patients in a Phase 2b clinical trial called CENTAUR to evaluate CVC in patients with NASH and liver fibrosis. On January 14, 2015, Tobira and Regado Biosciences (NASDAQ: RGDO) entered into a merger agreement that is expected to close in the second quarter of 2015. Learn more about Tobira at www.tobiratherapeutics.com.
Bladerunner
AI
